388 related articles for article (PubMed ID: 29428948)
21. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
[TBL] [Abstract][Full Text] [Related]
22. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
23. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
[TBL] [Abstract][Full Text] [Related]
24. Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy.
El-Sharkawi D; Basu S; Ocampo C; Qian W; D'Sa S; Hoskin PJ; Ardeshna KM
Leuk Lymphoma; 2012 Oct; 53(10):1949-52. PubMed ID: 22462615
[TBL] [Abstract][Full Text] [Related]
25. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).
Bento L; Díaz-López A; Barranco G; Martín-Moreno AM; Baile M; Martín A; Sancho JM; García O; Rodríguez M; Sánchez-Pina JM; Novelli S; Salar A; Bastos M; Rodríguez-Salazar MJ; González de Villambrosia S; Córdoba R; García-Recio M; Martínez-Serra J; Del Campo R; Luzardo H; García D; Hong A; Abrisqueta P; Sastre-Serra J; Roca P; Rodríguez J; Gutiérrez A;
Br J Haematol; 2020 Mar; 188(6):888-897. PubMed ID: 31782146
[TBL] [Abstract][Full Text] [Related]
26. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
27. Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells.
Jovanović MP; Jaković L; Bogdanović A; Marković O; Martinović VC; Mihaljević B
Vojnosanit Pregl; 2009 Sep; 66(9):738-43. PubMed ID: 19877554
[TBL] [Abstract][Full Text] [Related]
28. Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.
Yamamoto W; Nakamura N; Tomita N; Takeuchi K; Ishii Y; Takahashi H; Watanabe R; Takasaki H; Motomura S; Kobayashi S; Yokose T; Ishigatsubo Y; Sakai R
Leuk Lymphoma; 2014 Dec; 55(12):2721-7. PubMed ID: 24528218
[TBL] [Abstract][Full Text] [Related]
29. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
31. Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Lee HJ; Shin DH; Kim KB; Shin N; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY
Leuk Lymphoma; 2014 Sep; 55(9):2056-63. PubMed ID: 24304372
[TBL] [Abstract][Full Text] [Related]
32. [Influence of Peripheral Blood Lymphocyte/Monocyte ratio (LMR) and Its Ratio to Lactate Dehydrogenase on Prognosis of Patients with Diffuse Large B-Cell Lymphoma].
Yang D; Su LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1563-1569. PubMed ID: 33067955
[TBL] [Abstract][Full Text] [Related]
33. Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma.
Hong J; Yoon HH; Ahn HK; Sym SJ; Park J; Park PW; Ahn JY; Park S; Cho EK; Shin DB; Lee JH
Acta Haematol; 2013; 130(4):305-11. PubMed ID: 24008775
[TBL] [Abstract][Full Text] [Related]
34. Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma.
Jung SH; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
Acta Haematol; 2015; 133(1):10-7. PubMed ID: 24969101
[TBL] [Abstract][Full Text] [Related]
35. Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease.
Brauner S; Zhou W; Backlin C; Green TM; Folkersen L; Ivanchenko M; Löfström B; Xu-Monette ZY; Young KH; Møller Pedersen L; Boe Møller M; Sundström C; Enblad G; Baecklund E; Wahren-Herlenius M
J Intern Med; 2015 Sep; 278(3):323-32. PubMed ID: 25880119
[TBL] [Abstract][Full Text] [Related]
36. [Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma].
Zhang HY; Guan ZZ; Wang B; Huang HQ; Xia ZJ; Lin TY
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):381-4. PubMed ID: 18953841
[TBL] [Abstract][Full Text] [Related]
37. Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Hogan WJ; Markovic SN
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1804-12. PubMed ID: 25042737
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors in diffuse large B-cell lymphoma treated by risk-adopted therapy.
Tomita N; Kodama F; Motomura S; Koharazawa H; Fujita H; Harano H; Kanamori H; Ishigatsubo Y
Intern Med; 2006; 45(5):247-52. PubMed ID: 16595988
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Value of D-Dimer in Patients with Diffuse Large B-cell Lymphoma: A Retrospective Study.
Geng YD; Chen YR; Jin J; Wang XD; Zhang S; Li DJ
Curr Med Sci; 2019 Apr; 39(2):222-227. PubMed ID: 31016514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
